Esperion Therapeutics, INC

Esperion Therapeutics, Inc. announced the successful completion of its merger with Essence Parent Inc., transitioning from a publicly traded company to a wholly owned subsidiary.

Esperion Therapeutics, Inc. announced that its stockholders have approved the Agreement and Plan of Merger with Essence Parent Inc. and its subsidiary, Essence MergerCo Inc.

Esperion Therapeutics announces the expiration of the HSR Waiting Period for its merger with ArchiMed SAS affiliate, Essence Parent Inc., with stockholder approval pending.

Esperion Therapeutics announces German regulatory approval for its merger with ArchiMed affiliate Essence Parent Inc., with other conditions pending.

Esperion Therapeutics held its 2026 annual meeting, where stockholders approved an amendment to increase shares available under the 2022 Stock Option and Incentive Plan.

Esperion Therapeutics has completed the acquisition of Corstasis Therapeutics, adding the FDA-approved nasal spray Enbumyst to its cardiovascular portfolio.

Esperion Therapeutics reports Q1 2026 financial results while detailing a pending merger agreement and the recent acquisition of Corstasis Therapeutics.

Esperion Therapeutics reported an increased net loss for Q3 and the first nine months of 2025, despite growth in product sales and collaboration revenue, driven by higher operating and interest expenses.

Esperion Therapeutics reports a net loss of $12.7 million for Q2 2025, an improvement from the prior year, driven by robust product sales and new international collaborations, despite increased interest expenses and a material weakness in internal controls.

Esperion Therapeutics' Q1 2025 shows increased product sales but a decrease in collaboration revenue compared to Q1 2024, resulting in a net loss.

Esperion Therapeutics saw a significant increase in revenue for the third quarter of 2024, driven by both product sales and collaboration agreements.

Esperion Therapeutics saw a significant boost in revenue in the second quarter of 2024, primarily due to a settlement agreement and increased product sales, while also achieving expanded labels for its key products.

Esperion Therapeutics highlights FDA label expansions, strategic collaborations, and financial maneuvers in its 2024 annual report, aiming for sustained growth in the LDL-C and cardiovascular risk reduction market.

Esperion Therapeutics' 10-K filing outlines the company's stock structure, potential risks, and strategic focus on commercializing its cholesterol-lowering drugs.

Robert E. Hoffman, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

J Martin Carroll, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

Jay Shepard, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

Seth H. Z. Fischer, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

John Craig Thompson, a Director of Esperion Therapeutics, Inc., reported multiple transactions in common stock on July 13, 2026.

John B. Harlow Jr., Chief Commercial Officer of Esperion Therapeutics, Inc., reported a transaction in 424,536 shares of common stock on July 13, 2026.

Esperion Therapeutics announces its 2026 Annual Meeting of Stockholders to be held virtually on May 28, 2026, featuring key proposals including a 7,000,000 share increase to its 2022 Stock Option and Incentive Plan.

Esperion Therapeutics, Inc. has filed a definitive proxy statement with the SEC.

Esperion Therapeutics is asking stockholders to approve an amendment to its 2022 Stock Option and Incentive Plan to increase the number of shares available for issuance by 6,250,000.

Esperion Therapeutics is asking stockholders to approve amendments to its stock option and employee stock purchase plans at the upcoming annual meeting to increase the number of shares available for issuance.

Vanguard Capital Management has reported beneficial ownership of over 13.1 million shares, representing 5.08% of Esperion Therapeutics' common stock.

Wasatch Advisors LP has filed a Schedule 13G, reporting beneficial ownership of 1,930,185 shares of Esperion Therapeutics Inc. common stock, representing 0.7% of the class.

Glazer Capital, LLC and Paul J. Glazer have filed a Schedule 13G reporting an 8.15% beneficial ownership stake in Esperion Therapeutics, Inc.

Wasatch Advisors LP has reported beneficial ownership of 15,768,897 shares, representing 6.1% of the outstanding common stock of Esperion Therapeutics Inc.

The Vanguard Group reported a 0% beneficial ownership in Esperion Therapeutics Inc. common stock following an internal corporate realignment.

Two Seas Capital LP, along with its general partner and chief investment officer, reported a 4.7% passive beneficial ownership stake in Esperion Therapeutics, Inc. as of September 30, 2025.